B. Riley Financial’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.85M Buy
929,734
+266,358
+40% +$817K 0.63% 7
2025
Q4
$2.36M Sell
663,376
-148,170
-18% -$550K 1.01% 6
2025
Q3
$2.83M Buy
811,546
+349,546
+76% +$1.2M 1.92% 6
2025
Q2
$947K Buy
462,000
+312,000
+208% +$780K 1.06% 10
2025
Q1
$171K Buy
+150,000
New +$116K 0.22% 14

Other funds holding STLN

B. Riley Financial's STLN Position: Q1 2026 in Review

B. Riley Financial increased its Starling Oncology Institute, Inc. Common Stock (STLN) stake by 40% in Q1 2026, buying an estimated $817K and bringing the position to 929,734 shares worth $2.85M. The position accounts for 0.63% of the portfolio, ranked #7.

B. Riley Financial first reported a position in STLN in Q1 2025 and has held it in 5 quarters since. 115 funds tracked by Wall St. Rank hold STLN as of Q1 2026.

  • B. Riley Financial held 929,734 shares of Starling Oncology Institute, Inc. Common Stock worth $2.85M as of Q1 2026.
  • B. Riley Financial bought 266,358 Starling Oncology Institute, Inc. Common Stock shares in Q1 2026, an estimated $817K.
  • Starling Oncology Institute, Inc. Common Stock made up 0.63% of B. Riley Financial's portfolio in Q1 2026, its #7 holding.
  • B. Riley Financial first reported a position in Starling Oncology Institute, Inc. Common Stock in Q1 2025 and has held it in 5 quarters since.
  • 115 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q1 2026.

Based on B. Riley Financial's 13F filing for Q1 2026, filed 15 May 2026.